As Office Depot (ODP) Valuation Declined, Aristotle Fund LP Has Lifted Stake by $594,000; As Vertex Pharmaceuticals (VRTX) Market Valuation Rose, Bamco Lifted Its Holding

May 2, 2018 - By Marguerite Chambers

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Logo

Bamco Inc increased its stake in Vertex Pharmaceuticals Inc (VRTX) by 45.62% based on its latest 2017Q4 regulatory filing with the SEC. Bamco Inc bought 13,588 shares as the company’s stock rose 6.91% while stock markets declined. The institutional investor held 43,371 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $6.50M, up from 29,783 at the end of the previous reported quarter. Bamco Inc who had been investing in Vertex Pharmaceuticals Inc for a number of months, seems to be bullish on the $38.77 billion market cap company. The stock decreased 0.24% or $0.36 during the last trading session, reaching $152.12. About 375,341 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 76.59% since May 2, 2017 and is uptrending. It has outperformed by 65.04% the S&P500.

Aristotle Fund Lp increased its stake in Office Depot Inc. (ODP) by 4.82% based on its latest 2017Q4 regulatory filing with the SEC. Aristotle Fund Lp bought 198,000 shares as the company’s stock declined 39.24% with the market. The hedge fund held 4.31 million shares of the consumer services company at the end of 2017Q4, valued at $15.25M, up from 4.11 million at the end of the previous reported quarter. Aristotle Fund Lp who had been investing in Office Depot Inc. for a number of months, seems to be bullish on the $1.25B market cap company. The stock decreased 3.23% or $0.08 during the last trading session, reaching $2.24. About 423,104 shares traded. Office Depot, Inc. (NASDAQ:ODP) has declined 52.71% since May 2, 2017 and is downtrending. It has underperformed by 64.26% the S&P500.

Since January 5, 2018, it had 0 insider buys, and 1 insider sale for $4,637 activity.

Investors sentiment increased to 0.97 in Q4 2017. Its up 0.10, from 0.87 in 2017Q3. It improved, as 32 investors sold ODP shares while 82 reduced holdings. 40 funds opened positions while 71 raised stakes. 486.57 million shares or 5.44% more from 461.44 million shares in 2017Q3 were reported. Citadel Ltd has 1.14M shares for 0% of their portfolio. Stone Ridge Asset Ltd Liability reported 254,825 shares. Quinn Opportunity Ptnrs Limited Liability Company invested in 0.07% or 121,000 shares. Employees Retirement Systems Of Ohio reported 0% of its portfolio in Office Depot, Inc. (NASDAQ:ODP). Jefferies Limited Liability Co holds 0% or 69,700 shares. Fairpointe Ltd Limited Liability Company holds 31.12M shares. Mycio Wealth Partners Limited Com stated it has 16,360 shares. Macquarie Group owns 198,200 shares or 0% of their US portfolio. Neuberger Berman Group Ltd Company holds 0.02% or 4.43 million shares. Citigroup Inc owns 392,969 shares for 0% of their portfolio. Ancora Advisors Limited Liability Company holds 0.02% or 124,000 shares. Los Angeles Management And Equity, a California-based fund reported 43,516 shares. Stratos Wealth Prns Limited holds 0% or 788 shares. Us Financial Bank De reported 1,053 shares or 0% of all its holdings. Martingale Asset Lp holds 444,609 shares or 0.02% of its portfolio.

Among 12 analysts covering Office Depot (NASDAQ:ODP), 3 have Buy rating, 3 Sell and 6 Hold. Therefore 25% are positive. Office Depot had 21 analyst reports since September 8, 2015 according to SRatingsIntel. The rating was downgraded by JP Morgan on Monday, October 30 to “Underweight”. Telsey Advisory Group maintained Office Depot, Inc. (NASDAQ:ODP) rating on Friday, October 28. Telsey Advisory Group has “Market Perform” rating and $4.50 target. J.P. Morgan downgraded the stock to “Sell” rating in Monday, October 30 report. As per Thursday, July 27, the company rating was maintained by Jefferies. On Wednesday, May 11 the stock rating was downgraded by Jefferies to “Sell”. The stock has “Sell” rating by UBS on Wednesday, May 11. The stock has “Sector Weight” rating by KeyBanc Capital Markets on Tuesday, December 8. The company was maintained on Wednesday, June 14 by Jefferies. The firm has “Hold” rating given on Tuesday, December 13 by Loop Capital. Telsey Advisory Group maintained the shares of ODP in report on Tuesday, December 8 with “Outperform” rating.

Among 30 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 26 have Buy rating, 0 Sell and 4 Hold. Therefore 87% are positive. Vertex Pharmaceuticals had 102 analyst reports since July 31, 2015 according to SRatingsIntel. The stock has “Buy” rating by Argus Research on Thursday, February 4. Stifel Nicolaus maintained it with “Buy” rating and $109 target in Thursday, September 15 report. The firm earned “Buy” rating on Wednesday, October 5 by Jefferies. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Buy” rating given on Wednesday, September 6 by Robert W. Baird. Needham maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Thursday, October 26. Needham has “Buy” rating and $195.0 target. The stock has “Market Perform” rating by William Blair on Tuesday, November 1. Jefferies maintained the shares of VRTX in report on Thursday, October 26 with “Buy” rating. Morgan Stanley upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Friday, October 2 to “Overweight” rating. The firm has “Hold” rating given on Monday, August 24 by Vetr. The stock has “Buy” rating by Oppenheimer on Sunday, July 9.

Bamco Inc, which manages about $24.24B and $21.69B US Long portfolio, decreased its stake in Under Armour Inc (NYSE:UA) by 3.99M shares to 3.72 million shares, valued at $53.66 million in 2017Q4, according to the filing. It also reduced its holding in Okta Inc by 24,520 shares in the quarter, leaving it with 15,556 shares, and cut its stake in Servicenow Inc (NYSE:NOW).

Since October 31, 2017, it had 0 insider purchases, and 43 selling transactions for $105.97 million activity. LEIDEN JEFFREY M sold $3.61 million worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday, February 12. Arbuckle Stuart A also sold $336,345 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Tuesday, January 16. Another trade for 3,438 shares valued at $521,895 was sold by Chodakewitz Jeffrey. $116,511 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Graney Thomas. Sachdev Amit sold $2.68 million worth of stock. The insider ALTSHULER DAVID sold 1,796 shares worth $298,330.

Investors sentiment decreased to 1.34 in Q4 2017. Its down 0.28, from 1.62 in 2017Q3. It is negative, as 53 investors sold VRTX shares while 160 reduced holdings. 72 funds opened positions while 213 raised stakes. 232.48 million shares or 0.46% more from 231.42 million shares in 2017Q3 were reported. Northwestern Mutual Wealth Mgmt holds 0% or 1,068 shares. Arcadia Investment Mi accumulated 0.01% or 160 shares. Millennium Management Limited Company has invested 0.25% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Mitsubishi Ufj Hldgs reported 630 shares stake. Evercore Wealth Mgmt Ltd Co reported 2,730 shares. Tiverton Asset Mngmt Limited Liability Corporation invested 0.41% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Adage Capital Prtn reported 0.46% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Moreover, Employees Retirement Sys Of Texas has 0.23% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Fifth Third Natl Bank invested in 0% or 474 shares. Utah Retirement invested in 0.15% or 46,827 shares. Lourd Cap Lc holds 1,552 shares or 0.02% of its portfolio. Vanguard Grp has invested 0.12% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Hightower Advisors Lc holds 0.01% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 8,056 shares. Dupont Cap Mgmt invested in 46,171 shares or 0.16% of the stock. Kbc Grp Inc Inc Nv, Belgium-based fund reported 22,728 shares.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>